| 66.25 Delayed Data As of Dec 14 |  -1.04 / -1.55%Today’s Change | 58.33 Today|||52-Week Range 102.63 | -30.05% Year-to-Date |
| 5 Biotech Stocks Set to Bounce Back in '19 After a Rough Ride Dec 14 / Zacks.com - Paid Partner Content | AstraZeneca's Imfinzi Fails in Head and Neck Cancer Study Dec 07 / Zacks.com - Paid Partner Content |
| Roche to Create Companion Diagnostic Test for Merck's Keytruda Dec 12 / Zacks.com - Paid Partner Content | Shire (SHPG), Takeda Shareholders Approve $62 Billion Merger Dec 06 / Zacks.com - Paid Partner Content |
| 5 Top Drug/Biotech Merger & Acquisition Targets for 2019 Dec 10 / Zacks.com - Paid Partner Content | Incyte (INCY) Announces Positive Data on Jakafi for GVHD Dec 04 / Zacks.com - Paid Partner Content |
| Previous close | 67.29 |
| Today’s open | 66.61 |
| Day’s range | 65.66 - 67.64 |
| Volume | 1,184,886 |
| Average volume (3 months) | 1,491,713 |
| Market cap | $13.6B |
| Earnings growth (last year) | -378.18% |
| Earnings growth (this year) | +135.55% |
| Earnings growth (next 5 years) | +47.45% |
| Revenue growth (last year) | +38.93% |
| P/E ratio | NM |
| Price/Sales | 12.61 |
| Price/Book | 8.30 |
| Today’s change | Today’s % change | |
|---|---|---|
| BMRNBiomarin Pharmaceuti... | -0.78 | -0.83% |
| JAZZJazz Pharmaceuticals... | -1.54 | -1.08% |
| PRGOPerrigo Company PLC | -1.52 | -2.60% |
| SGENSeattle Genetics Inc | -0.52 | -0.85% |
| Next reporting date | February 14, 2019 |
| EPS forecast (this quarter) | $0.19 |
| Annual revenue (last year) | $1.5B |
| Annual profit (last year) | -$313.1M |
| Net profit margin | -20.38% |
Sector Health Technology |
Industry Biotechnology |
Chairman, President & Chief Executive Officer Hervé Hoppenot |
Chief Financial Officer & Executive Vice President David W. Gryska |
Corporate headquarters Wilmington, Delaware |
